Published Date: 27/11/2006
Category: Therapies & Markets
The global market for CNS disorders is now one of the largest therapeutic sectors with sales estimated at almost US$92 billion in 2007.In the new edition of this best-selling report we have identified 60 drugs or therapeutic agents which we believe have the potential to reach the market by 2014, and could offer significant advancement in treatment and address areas of large unmet clinical need.All CNS categories have attracted, and continue to attract, significant investment from the pharmaceutical industry in the development of safer, more efficacious medicines. In some areas such as depression and schizophrenia, many of the new agents are based on similar chemical classes to existing treatments (“me too”), but may be better tolerated and/or more efficacious.In contrast, other areas such as Parkinson’s disease (PD), Alzheimer’s disease (AD) and multiple sclerosis (MS) have seen a plethora of innovative medicines emerging that have novel mechanisms of actions. These may lend themselves for use as both monotherapies and in combination with existing therapies in the symptomatic treatment of disease or in some cases in modifying the course of the disease. Several drugs are being developed for multiple indications and this is particularly apparent in depression and schizophrenia where cognitive symptoms are addressed.The majority of companies focus on a diverse range of CNS disorders attempting to address unmet clinical need and large patient populations. However, in some markets such as MS, a handful of companies dominate the market, whilst in AD and PD there are many players, including biotechnology and biopharmaceutical companies, where large specialist sales forces may not be necessary to promote novel medicines.
What are the global CNS sales 2007-2014?Who are the major palyers?What products are in development?Which approved products face patent exposure?Who will be the winners and losers?
This report provides a complete review of the markets, products and pipeline prospects for 5 key CNS areas. Firstly, the individual markets, the major players, treatment drivers, market resistors, potential patient populations and unmet clinical needs have been analysed, in addition to which, many therapies and pipeline products currently in Phase II and III development have been evaluated. Secondly, we have reviewed each of the leading brands and potential new brands and identified their key attributes, based on a number of criteria including:Novelty/rationale for mechanism of action.Proof of concept/clinical data.Management/clinical expertise.Competition within the marketplace/gaining share of voice through marketing, advertising and sales force ability. Risks associated with developing a drug within a therapeutic class.Thirdly, we have established a competitor ratio analysis based on each of the criteria mentioned above. Each criterion attracts an award of up to 10 points, with a maximum score of 50, thus enabling the establishment of an Espicom “ranking table” in each segment of the market, dependent on the drug/company’s relative attributes and enabling comparison across therapy areas.Thirdly, we have established a competitor ratio analysis based on each of the criteria mentioned above. Each criterion attracts an award of up to 10 points, with a maximum score of 50, thus enabling the establishment of an Espicom “ranking table” in each segment of the market, dependent on the drug/company’s relative attributes and enabling comparison across therapy areas.